Stockscreener 앱 받기
5.88
8.29%
0.45
시간 외 거래:
5.70
-0.18
-3.06%
전일 마감가:
$5.43
열려 있는:
$5.44
하루 거래량:
5.20M
Relative Volume:
3.31
시가총액:
$555.36M
수익:
$829.00M
순이익/손실:
$-399.90M
주가수익비율:
-1.3624
EPS:
-4.3159
순현금흐름:
$-23.20M
1주 성능:
+29.52%
1개월 성능:
+52.73%
6개월 성능:
-9.26%
1년 성능:
+10.32%
1일 변동 폭
$5.34
$5.90
1주일 범위
$4.39
$5.90
52주 변동 폭
$3.53
$8.59
Myriad Genetics Inc Stock (MYGN) Company Profile
명칭
Myriad Genetics Inc
전화
801-584-3600
주소
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN vs TMO, DHR, IDXX, A, NTRA
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
5.88 | 512.85M | 829.00M | -399.90M | -23.20M | -4.3159 |
TMO
Thermo Fisher Scientific Inc
|
513.03 | 187.95B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
196.19 | 136.75B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
551.50 | 43.78B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
136.01 | 38.27B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
261.91 | 37.34B | 2.50B | -226.32M | 71.51M | -1.6412 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-21 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-12 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | 개시 | Craig Hallum | Buy |
| 2024-12-10 | 개시 | UBS | Neutral |
| 2024-12-09 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-27 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-03 | 재개 | Jefferies | Underperform |
| 2024-05-08 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | 재개 | Piper Sandler | Neutral |
| 2023-12-19 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-07-05 | 재개 | JP Morgan | Underweight |
| 2023-05-23 | 업그레이드 | Goldman | Sell → Buy |
| 2023-01-18 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | 개시 | Stephens | Equal-Weight |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-06-03 | 개시 | Goldman | Sell |
| 2019-09-26 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2019-07-29 | 다운그레이드 | Needham | Strong Buy → Hold |
| 2019-07-09 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2019-03-12 | 재확인 | Needham | Strong Buy |
| 2019-01-03 | 개시 | Needham | Strong Buy |
| 2018-11-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | 개시 | Goldman | Sell |
| 2018-01-22 | 재확인 | Barclays | Equal Weight |
| 2018-01-05 | 개시 | BTIG Research | Buy |
| 2017-10-02 | 재개 | Leerink Partners | Mkt Perform |
| 2017-08-09 | 재확인 | Barclays | Equal Weight |
| 2017-02-08 | 업그레이드 | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | 개시 | Deutsche Bank | Sell |
| 2016-10-10 | 다운그레이드 | Ladenburg Thalmann | Neutral → Sell |
모두보기
Myriad Genetics Inc 주식(MYGN)의 최신 뉴스
Price to sales forward of Myriad Genetics, Inc. – NASDAQ:MYGN - TradingView
Price to book forward of Myriad Genetics, Inc. – NASDAQ:MYGN - TradingView
Myriad Genetics, Inc. Actuals & Estimates (NASDAQ:MYGN) - TradingView
897518 Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Myriad Genetics, Inc. – LS:897518 - TradingView
Price to sales forward of Myriad Genetics, Inc. – LS:897518 - TradingView
Enterprise value to revenue forward of Myriad Genetics, Inc. – NASDAQ:MYGN - TradingView
Enterprise value to revenue forward of Myriad Genetics, Inc. – LS:897518 - TradingView
MYGN Forecast — Price Target — Prediction for 2027 - TradingView
Myriad Genetics, Inc. Actuals & Estimates (FWB:MYD) - TradingView
Myriad Genetics clears analyst hurdle, shares steady on NASDAQ - Ad-hoc-news.de
MYD Forecast — Price Target — Prediction for 2027 - TradingView
Why Is Myriad Genetics (MYGN) Stock Rocketing Higher Today - Yahoo Finance
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication - Sahm
Director at Myriad Genetics (MYGN) reports 195,507-share Common Stock stake - Stock Titan
Myriad Genetics expands cancer detection test availability By Investing.com - Investing.com Australia
Form 8K Myriad Genetics Inc For: 23 June By Investing.com - Investing.com Australia
MYGN PE Ratio & Valuation, Is MYGN Overvalued - Intellectia AI
Myriad Genetics expands cancer detection test availability - Investing.com
Myriad Genetics director Daniel Skovronsky resigns from board By Investing.com - Investing.com Australia
Myriad Genetics director Daniel Skovronsky resigns from board - Investing.com UK
MYRIAD GENETICS, INC. 8-K Filing: Key Company Information and SEC Compliance Details for June 2026 - Minichart
Myriad widens cancer test access as breast study bolsters its case - Stock Titan
Board member Skovronsky exits Myriad Genetics (NASDAQ: MYGN) - Stock Titan
Myriad Genetics Inc (MYGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Myriad Genetics Inc (MYGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Myriad Genetics Inc (MYGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Myriad Genetics StockAnalyst views and sector comparison on a quiet news day - Ad-hoc-news.de
Ovarian Cancer Diagnostics Market Size to Reach USD 8.08 Billion by 2035 | SNS Insider - GlobeNewswire Inc.
Myriad Genetics Inc (MYGN) Institutional Confidence - TradingKey
Myriad Genetics Inc (MYGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Myriad Genetics Inc (MYGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Myriad Genetics Inc (MYGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Myriad Genetics Inc (MYGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Myriad Genetics Inc (MYGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Myriad Genetics (NASDAQ: MYGN) CEO adds 3,542 shares via employee stock purchase plan - Stock Titan
Executive at Myriad Genetics (MYGN) adds 5,000 shares via ESPP plan - Stock Titan
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Rating of "Hold" from Analysts - MarketBeat
Insider Sell Alert: Rashmi Kumar Sells 15,000 Shares of Myriad G - GuruFocus
Myriad Genetics (MYGN) director sells 15,000 shares under 10b5-1 plan - Stock Titan
Should You Add Myriad Genetics Stock to Your Portfolio Right Now? - TradingView
[144] MYRIAD GENETICS INC SEC Filing - Stock Titan
Director at Myriad Genetics (MYGN) receives 59,701 restricted stock units - Stock Titan
Myriad Genetics (MYGN) director awarded 59,701 restricted stock units - Stock Titan
Myriad Genetics (MYGN) grants 59,701 RSUs to director Mark Davis - Stock Titan
[Form 4] MYRIAD GENETICS INC Insider Trading Activity - Stock Titan
Myriad Genetics (MYGN) director receives 59,701 restricted stock units in equity grant - Stock Titan
Myriad Genetics (NASDAQ: MYGN) director receives 59,701 restricted stock units - Stock Titan
Myriad Genetics (MYGN) grants 59,701 RSUs to board director Bisaro - Stock Titan
Myriad Genetics (NASDAQ: MYGN) director granted 59,701 restricted stock units in equity award - Stock Titan
Myriad Genetics (NASDAQ: MYGN) shareholders approve 2026 equity and purchase plans - Stock Titan
Myriad Genetics Inc (MYGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.76%
0.62%
자본화:
|
볼륨(24시간):